Abstract
Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Design, synthesis and structure activity relationship are reported.
Keywords:
Anti-tumor activity; Dual inhibitor; Mammalian target of rapamycin; Phosphoinositide 3-kinase.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Binding Sites
-
Drug Design*
-
Enzyme Activation / drug effects
-
Inhibitory Concentration 50
-
Mice
-
Molecular Structure
-
Naphthyridines / chemistry*
-
Naphthyridines / pharmacokinetics
-
Naphthyridines / pharmacology*
-
Phosphoinositide-3 Kinase Inhibitors*
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / isolation & purification
-
Protein Kinase Inhibitors / pharmacology*
-
Signal Transduction / drug effects
-
Structure-Activity Relationship
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
Substances
-
Naphthyridines
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors
-
TOR Serine-Threonine Kinases